FDA requires vitamin B6 deficiency warning for carbidopa/levodopa products
FDA required a new warning about vitamin B6 (pyridoxine) deficiency and associated seizures for drug products containing carbidopa/levodopa. Carbidopa inhibits aromatic L-amino acid decarboxylase, which uses B6 as a cofactor; prolonged use can deplete systemic B6 stores.
Carbidopa ↗ is a peripheral DOPA decarboxylase inhibitor added to levodopa to prevent its peripheral conversion to dopamine before reaching the brain. Dopa decarboxylase uses pyridoxal-5′-phosphate (the active form of B6) ↗ as a cofactor. Prolonged carbidopa use can progressively deplete systemic B6, leading to deficiency symptoms including peripheral neuropathy, glossitis, and — in severe cases — seizures.
Who is most at risk
Patients on long-term carbidopa/levodopa for Parkinson's disease ↗ are at highest risk, particularly those with poor nutritional intake, malabsorption, or co-existing conditions increasing B6 demand. FDA recommends clinicians consider monitoring B6 levels in long-term users and supplementing if deficiency is confirmed. The full updated prescribing information is on DailyMed ↗.
FAQ
Does a Boxed Warning mean a drug is being withdrawn?
No. A Boxed Warning ↗ (also called a Black Box Warning) is the FDA's strongest label caution, but the drug remains on the market. It means the agency has determined that a risk is serious enough to require prominent, standardised labelling. The drug continues to be prescribed under appropriate clinical conditions. See the FDA's patient guide to Boxed Warnings ↗.
Where can I read the full updated label?
All current FDA-approved prescribing information is available on DailyMed ↗, maintained by the National Library of Medicine (NLM). Search by drug name to find the most recent label version. Historical label versions are also archived there.